At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01877 JUNSHI BIO
Closed 03-04 16:08:16
17.930
-0.080
-0.44%
High18.250
Low17.580
Vol2.41M
Open17.810
D1 Closing18.010
Amplitude3.72%
Mkt Cap18.41B
Tradable Cap4.66B
Total Shares1.03B
T/O43.10M
T/O Rate0.93%
Tradable Shares260.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
JUNSHI BIO (01877) Releases February 2026 Monthly Return on Securities Movements
Junshi Bio (01877) Issues Profit Warning, Anticipates 2025 Net Loss Attributable to Owners of Approximately 873 Million Yuan, Representing a 31.85% Year-on-Year Reduction in Losses
Hong Kong Stocks Movement | Select Pharmaceutical Stocks Rally in Afternoon Session: CANSINOBIO (06185) Surges Over 10%, JUNSHI BIO (01877) Gains Over 5%
Shanghai Junshi Biosciences Co Ltd is a China-based company mainly engaged in innovation-driven biopharmaceutical business. The Company's main businesses are the discovery, clinical research and development of innovative drugs. The Company's main products include teriprizumab injection, Etesevimab, adalimumab injection and other drugs, which are used to treat malignant tumors, autoimmune system diseases, chronic metabolic diseases, nervous system diseases and infectious diseases. The Company is also engaged in the clinical research and development of recombinant humanized anti-PCSK9 monoclonal antibody injection and other drugs. The Company provides its products for domestic and overseas markets.